Memantin Ratiopharm

Memantine, the active ingredient in Memantin Ratiopharm, is a NMDA receptor antagonist presented as a tablet for oral use. It is indicated for the treatment of Alzheimer’s disease in adult patients, helping to reduce excitotoxic neuronal damage.

GNH USA supplies Memantin Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantin Ratiopharm is used in the management of Alzheimer’s disease, a neurodegenerative condition affecting cognition and daily function. - Alzheimer’s disease: improves cognition, global functioning and activities of daily living in mild to moderate stages.

Memantin Ratiopharm may cause a range of adverse reactions. Patients should be aware of both frequent and less common events.

Common Side Effects: - Dizziness: transient light‑headedness, especially after dose initiation. - Headache: mild to moderate intensity, often resolves with continued therapy. - Constipation: reduced bowel movements, manageable with diet or laxatives. - Confusion: occasional disorientation, particularly in early treatment. - Fatigue: feeling unusually tired or low energy. - Hypertension: modest increase in blood pressure in some individuals.

Serious or Rare Side Effects: - Seizures: rare occurrence, requires immediate medical attention. - Cardiac arrhythmia: abnormal heart rhythms reported infrequently. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic injury: elevated liver enzymes or hepatitis. - Suicidal ideation: emergent thoughts of self‑harm, necessitating urgent evaluation. - Neuroleptic malignant syndrome: extremely rare but life‑threatening condition.

Before initiating Memantin Ratiopharm, clinicians should consider several safety aspects. - Renal impairment: adjust dose or monitor closely in patients with reduced kidney function. - Hepatic impairment: use with caution; liver function tests may be warranted. - Concomitant NMDA antagonists: avoid combined use to reduce risk of additive neurotoxicity. - Cardiovascular disease: monitor blood pressure and heart rhythm regularly. - Pregnancy and lactation: safety not established; weigh potential benefits against risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Memantin Ratiopharm can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neurotoxicity. - Ketamine: additive CNS effects and heightened risk of seizures. - Other NMDA receptor antagonists: may amplify adverse neurological events.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: memantine may attenuate blood‑pressure‑lowering effects. - CNS depressants (e.g., benzodiazepines): increased sedation or dizziness. - Diuretics: potential for electrolyte disturbances, especially potassium. - Anticholinergic drugs: may worsen confusion or cognitive impairment.